LumiThera Inc. announced a distribution agreement with Miloftalmica to exclusively distribute the Valeda™ Light Delivery System for the treatment of dry age-related macular degeneration (AMD) in Italy. Miloftalmica is leading the Italian ophthalmology market since 1983, pursuing Innovation and Excellence. (LumiThera is a commercial-stage medical device company focused on developing photobiomodulation (PBM) therapies for ocular disorders and disease).
“Our new exciting partnership with LumiThera is fully consistent with the strategy and growth objectives of Miloftalmica, combining innovation and excellence in technology. LumiThera’s breakthrough light delivery system is a value added to Miloftalmica’s product portfolio,” stated Andrea Pagani, Miloftalmica CEO. “LumiThera indeed enables us to offer the first approved treatment for people suffering from dry AMD, the leading cause of adult blindness worldwide.”
“The Distribution agreement with Miloftalmica allows LumiThera to expand commercialization in Europe and establishes a collaboration with a partner providing complementary diagnostic and imaging technologies to our treatment for dry AMD,” stated Clark Tedford, Ph.D., LumiThera President and CEO. “Miloftalmica is a leader in providing innovative technologies to the ophthalmologist and we are excited to be working with them to provide our treatment for dry AMD.”
The Valeda™ Light Delivery System therapy consists of a series of light-based treatments to the retinal cells, resulting in improved energy production and addressing inflammation, ischemia and metabolic dysfunction that contribute to the disease.